Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial;Cancer du pancréas localement évolué non resécable: chimioradiothérapie d'induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine: résultats définitifs de l'étude de phase III 2000-2001de la FFCD et de la SFRO

Cancer/Radiotherapie

Volumn 15, Issue 3, 2011, Pages 182-191

  Barhoumi, M ^a   Mornex, F ^a   Bonnetain, F ^b,c,d   Rougier, P ^e   Mariette, C ^f   Bouche O ^g   Bosset, J F ^h   Aparicio, T ⁱ   Mineur, L ^j   Azzedine, A ^k   Hammel, P ^l   Butel, J ^m   Stremsdoerfer, N ⁿ   Maingon, P ^b   Bedenne, L ^c,d,o   Chauffert, B ^b,c,d  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c Chu   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g REIMS UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j INSTITUT SAINTE CATHERINE   (France)

^k CENTRE HOSPITALIER D AVIGNON   (France)

^l BEAUJON HOSPITAL   (France)

^m Hôpital d'Abbeville   (France)

ⁿ Centre Hospitalier Pierre Oudot   (France)

^o HÔPITAL DU BOCAGE   (France)

more..

Author keywords

5 fluoro uracil; Chemoradiotherapy; Cisplatin; Gemcitabin; Maintenance; Overall survival; Pancreatic cancer; Randomized phase iii trial

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; HUMAN; INOPERABLE CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 79956219838     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.10.001     Document Type: Article

References (31)

1. Riall T.S., Nealon W.H., Goodwin J.S., Zhang D., Kuo Y.F., Townsend C.M., et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 2006, 10:1212-1223.
2. Moertel C.G., Frytak S., Hahn R.G., O'Connell M.J., Reitemeier R.J., Rubin J., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluoro-uracil), and high dose radiation +5-fluoro-uracil. Cancer 1981, 48:1705-1710.
3. Gastro-intestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1998, 80:751-755.
4. Klaassen D.J., MacIntyre J.M., Catton G.E., Engstrom P.F., Moertel C.G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluoro-uracil - an Eastern cooperative oncology group study. J Clin Oncol 1985, 3:373-378.
5. Burris H.A., Moore M.J., Anderson J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
6. André T., Balosso J., Louvet C., Hannoun L., Houry S., Huguier M., et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluoro-uracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 2000, 46:903-911.
7. Azria D., Ychou M., Jacot W., Thezenas S., Lemanski C., Senesse P., et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluoro-uracil and cisplatin. Pancreas 2002, 25:360-365.
8. Kornek G.V., Schratter-Sehn A., Marczell A., Depisch D., Karner J., Krauss G., et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluoro-uracil, leucovorin and cisplatin. Br J Cancer 2000, 82:98-103.
9. Snady H., Bruckner H., Cooperman A., Paradiso J., Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000, 89:314-327.
10. Mornex F., Girard N., Scoazec J.Y., Bossard N., Ychou M., Smith D., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluoro-uracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006, 65:1471-1478.
11. Blackstock A.W., Tepper J.E., Niedzwiecki D., Hollis D.R., Mayer R.J., Tempero M.A. l. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003, 34:107-116.
12. Brade A., Brierley J., Oza A., Gallinger S., Cummings B., Maclean M., et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 2007, 67:1027-1036.
13. Goldstein D.R., Van Hezel G., Walpole E., Underhill C., Kotasek D., Michael M., et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 2007, 97:464-471.
14. Haddock M.G., Swaminathan R., Foster N.R., Hauge M.D., Martenson J.A., Camoriano J.K., et al. Gemcitabin, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007, 25:2567-2572.
15. Ko A.H., Quivey J.M., Venook A.P., Bergsland E.K., Dito E., Schillinger B., et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:809-816.
16. Kurt E., Kurt M., Kanat O., Cetintas S.K., Aygun S., Palazoglu T., et al. Phase II study of induction chemotherapy with gemcitabine plus 5-fluoro-uracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer. Tumori 2006, 92:481-486.
17. Magnino A., Gatti M., Massucco P., Spertia E., Faggiuolo R., Regge D., et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 2005, 68:493-499.
18. Murphy J.D., Adusumilli S., Griffith K.A., Ray M.E., Zalupski M.M., Lawrence T.S., et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
19. Okusaka T., Ito Y., Ueno H., Ikeda M., Takezako Y., Morizane C., et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004, 91:673-677.
20. Wilkowski R., Boeck S., Ostermaier S., Sauer R., Herbst M., Fietkau R., et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin versus chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer - a multi-centre randomised phase II study. Br J Cancer 2009, 101:1853-1859. [Epub 2009 Nov 10].
21. Glimelius B., Hoffman K., Sjödén P.O., Jacobsson G., Sellström H., Enander L.K., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600.
22. Park J.K., Ryu J.K., Lee J.K., Yoon W.J., Lee S.H., Kim Y.T., et al. Gemcitabine chemotherapy versus 5 fluoro-uracil based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006, 33:397-402.
23. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
24. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
25. Huguet F., Girard N., Guerche C.S., Hennequin C., Mornex F., Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009, 27:2269-2277. [Epub 2009 Mar 23].
26. Sultana A., Tudur Smith C., Cunningham D., Starling N., Tait D., Neoptolemos J.P., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007, 96:1183-1190.
27. Yip D., Karapetis C., Strickland A., Steer C.B., et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006, 3:CD002093.
28. Bachet J.B., Mitry E., Lepere C., Declety G., Vaillant J.N., Parlier H., et al. Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?. Gastroenterol Clin Biol 2007, 31:151-156.
29. Huguet F., André T., Hammel P., Artru P., Balosso J., Selle F., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
30. Krishnan S., Rana V., Janjan N.A., Varadhachary G.R., Abbruzzese J.L., Das P., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
31. Camacho D., Reichenbach D., Duerr G.D., Venema T.L., Sweeney J.F., Fisher W.E. Value of laparoscopy in the staging of pancreatic cancer. J Pancreas 2005, 6:552-561.